WHO ICTRP trial
A safety, tolerability, and pharmacokinetic study of single- and…
NL-OMON54964 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON54964 |
|---|---|
| Public title | A safety, tolerability, and pharmacokinetic study of single- and multipleascending doses of LY3473329 in healthy subjects. |
| Scientific title | A safety, tolerability, and pharmacokinetic study of single- and multipleascending doses of LY3473329 in healthy subjects. - SAD/MAD study of LY3473329 in Healthy Subjects. |
| Primary sponsor | Eli Lilly |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Hyperlipidemie fat metabolism disorder Hyperlipidemia;fat metabolism disorder;Hyperlipidemia |
| Interventions | Group A1 on Day 1 LY3473329 1 milligram (mg) or placebo, once Group A2 on Day 1 LY3473329 10 mg or placebo, once Group A3 on Day 1 LY3473329 30 mg or placebo once Group A4 on Day 1 LY3473329 100 mg or placebo, once Group A5 on Day 1… |
| Registration date | Mar 1, 2021 |
| Target size | 113 |
| Secondary IDs | 2020-002522-91;NL74576.056.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: